Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

(MedRxiv). Because NAD+ is not bioavailable and cannot effectively raise NAD+ levels in the body, supplementing with NAD+ itself is not recommended. Furthermore, oral or intravenous NAD+ supplementation has not been well studied in humans, and its...

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and...

Experic appoints Jeffrey Shane as Chief Commercial Officer

him to lead our commercial team and support our growth.” During his tenure at Harro Höfliger, the company established itself as a premium equipment supplier to the biopharmaceutical industry. Under his leadership, the business expanded beyond...

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle...

To advance gene therapy development and manufacturing, ProBio has launched GMP AAV manufacturing services at its Hopewell facility

rigorous in-process controls and regulatory alignment at every step." With this launch, ProBio continues to position itself as a strategic partner for gene therapy innovators—offering agile, phase-appropriate manufacturing solutions that evolve...

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients...

To Redefine Specialty Care, Craft Telemedicine Launches with a Human-Centered Platform

Craft Telemedicine is actively seeking partnerships with high-quality compounding pharmacies nationwide, positioning itself as the preferred telemedicine platform for pharmacies seeking to grow their patient base without compromising their values...

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

pain, diarrhea, and nausea, which were not observed with Niagen IV. A common misconception is that the NAD+ molecule itself is bioavailable and that consumers can experience elevated NAD+ levels by taking NAD+ itself orally or intravenously. As a...

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established itself as a key player in the Latin American pharmaceutical market through its robust distribution network and strategic...

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

and services in more than 125 countries. About Cyfuse Biomedical K.K.: Cyfuse Biomedical K.K. (Securities Code: 4892, TSE Growth) is a regenerative medicine startup founded in 2010. Using its proprietary bio 3D printing technology, which creates...

Automated red blood cell exchange boosts quality of life for sickle cell patients

and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

Galmed releases Phase 3 Aramchol results in Hepatology.

MASH will be combination therapy. The company further believes that Aramchol' s unique mechanism of action differentiates itself from others in the competitive landscape, potentially positioning it to work as a potent anti-fibrotic compound...

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

the Pharmacy Payor Rate Transparency Monitor at the National Association of Chain Drug Stores – Total Store Expo (NACDS TSE), to be held August 17-19 in Boston. The pharmacy-specific interactive visualization tool was developed to provide...

Biosyngen's BRG01 gets FDA approval for Phase II clinical trial.

therapies and recognizes Biosyngen's innovation and R&D capability in cellular immunotherapy. Biosyngen has established itself as a leading biotech with a portfolio of cell therapies, including CAR-T, TCRT, and TIL, addressing various solid tumors...

Innocan Pharma submits Investigational New Animal Drug application to FDA's Veterinary Center.

in veterinary medicine." Dr. Eyal Kalo, R&D Director at Innocan, added, "LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic...

FDA Clears Rika Plasma Donation System's Individualized Nomogram

and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

ONFAB, High Potent Containment Provider, Expands into USA Market

critical processes, especially those involving High Potent Active Pharmaceutical Ingredients (HPAPIs). ONFAB prides itself on high standards of customer service and manufacturing and is ISO 9001 accredited. the internationally recognized standard...

FAQs

How does Pharmaceutical-Era.com different from other event promotion portals? Pharmaceutical-Era.com distinguishes itself by being the premier event promotion platform dedicated solely to the pharmaceutical industry. Our specialized approach...

Results 1 - 18 of 18